Valerie Durkalski-Mauldin, M.P.H., Ph.D.

Professor
Department: Public Health Sciences
Programs: Cellular Injury, Inflammation, Fibrosis, End Organ Disease

 

 

Research Interests:

Dr. Durkalski-Mauldin’s research interests are focused on collaborative studies of patients' digestive and liver diseases. Most recently, she collaborated with Dr. Joe Elmunzer (a DDRCC Full Member) to complete the NIDDK-funded multicenter randomized clinical trial - Stent vs Indomethacin for Preventing Post-ERCP Pancreatitis (SVI) clinical trial which was published in Lancet in January 2024. Dr. Durkalski-Mauldin continues to work with the study team on a number of secondary manuscripts from this important trial and has a number of abstracts submitted to the 2024 DDW meeting.

Dr. Durkalski-Mauldin has a number of additional digestive disease research projects underway, stemming from her involvement and leadership in NIDDK-funded clinical trial grants. She serves as a PI (multiple PI mechanism) in the multicenter Sphincterotomy for Acute Recurrent Pancreatitis (SHARP Trial) with Drs Greg Cote and Dhiraj Yadav, which is examining the impact of miES on the natural history of iRAP in patients with pancreas divisum. Durkalski-Mauldin is also a PI (again, multiple PI mechanism) of the NIDDK-funded multicenter randomized trial of Surveillance Versus Endoscopic Eradication Therapy for Patients with Barrett’s Esophagus and Low-Grade Dysplasia – The SURVENT Trial. She has collaborated extensively with Drs Joe Elmunzer and Puja Elias (a DDRCC Associate Member), who are site PIs for these two trials, respectively.

A transformative effort in Durkalski-Mauldin’s research career has been in acute liver injury, where I have worked with national consortia in adult and pediatric populations. She has been a multiple PI in the NIDDK-funded Acute Liver Failure Study Group, where she is analyzing a wealth of data collected over the past 20 years. She has worked extensively with Dr. David Koch (a DDRCC Associate Member), having published one of the study group’s most notable contributions – a prognostic calculator for acute liver failure.

Most recently, she has worked with external collaborators to identify prognostic biomarkers (Kwan R et al., Clin Gastro Hep 2023) and further studied patients with indeterminate causes of acute liver failure (Patel PV et al. Clin Transplant 2023). Dr. Durkalski-Mauldin is also a multiple PI of the pediatric acute liver failure Immune Tolerance Network - which is currently conducting an NIDDK-funded multicenter clinical trial titled Pediatric Acute Liver Failure Treatment for Immune-Mediated Pathophysiology (TRIUMPH). This is a double-blind, three-arm-randomized, placebo-controlled trial of high-dose methylprednisolone or equine anti-thymocyte globulin. Durkalski-Mauldin remains extremely active in this study, including in ongoing conduct of the trial, data acquisition, and data analysis.

Publications:

PubMed Collection

Recent Publications